CommercialPrior AuthMedium impact
Rituximab Non-Oncology
Blue Cross & Blue Shield of Mississippi·MS · Rheumatology, Neurology, Nephrology +3 more·Medical Policy
We identified it
Jun 20, 2026
Summary
This is a fresh prior authorization policy for rituximab (Ruxience and Truxima) used for non-cancer conditions. The policy requires prior authorization for multiple autoimmune and rheumatologic conditions including rheumatoid arthritis, vasculitis, pemphigus vulgaris, and other complex conditions with specific clinical criteria that must be met.
Action Required
Immediately: Billing team must update prior authorization requirements for rituximab biosimilars (Ruxience and Truxima) for all non-oncology indications. Update billing system to flag these medications for prior auth. Providers must document specific clinical criteria including previous treatment failures, contraindications, and required combination therapies. Ensure hepatitis B screening documentation is included. Claims will be denied without proper prior authorization.